

Emergent Technologies Portfolio Company Enters into License Agreement with Xencor

Austin, TX – January 12, 2016 – Emergent Technologies, Inc. announced today that its portfolio company, Receptor Logic, has entered into an exclusive License Agreement with Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for autoimmune diseases, asthma and allergic diseases, and cancer. The agreement gives Xencor the exclusive worldwide rights to use a T-Cell Receptor Mimic (TCRm) monoclonal antibody against the target NY-ESO1, developed by Receptor Logic, for cancer treatment.

“Our expertise in cancer target identification, when coupled with our development of TCRm monoclonal antibodies to cancer targets, provides a powerful pipeline for immuno-oncology drug development” said Chief Scientist William Hildebrand, Ph.D. “By identifying HLA/cancer antigen targets and making TCRm monoclonal antibodies to these targets, we provide industry partners with a steady stream of more personalized cancer therapeutics.”

“This agreement with Xencor reflects the significant value of our platform as we continue to advance into personalized medicine,” said Thomas Harlan, CEO of Receptor Logic and its related company, Pure MHC. “We’re excited to provide one of our TCRm antibodies to Xencor to assist the company in its cancer therapeutic development efforts.”

About Receptor Logic, Inc. and Pure MHC, LLC

Pure MHC, LLC, the market facing entity for the Receptor Logic TCRm technology, is an immunology company focused on MHC-based diagnostics and therapeutics providing novel solutions for the treatment of infectious diseases and cancers. Pure MHC and Receptor Logic were formed and are managed by Emergent Technologies, Inc.

About Emergent Technologies, Inc.

Austin, TX based Emergent Technologies, Inc. (Emergent) is a leading innovation solutions company that identifies, manages, develops and partners to turn game-changing scientific discoveries into market-driven products. Emergent's diverse business and technical team uses its unique innovation process to transform scientific breakthroughs into technology platforms with multiple applications, maximizing the value of promising ideas and underutilized intellectual properties without the risk associated with commercial development. The company applies its experience and expertise to provide investors, entrepreneurs, start-up companies and industry partners' access to innovative solutions to advance initiatives and protect and grow core businesses with novel, differentiating technology. For more information, visit www.emergenttechnologies.com.

###

Media Contact:

Cameron Mackie
Emergent Technologies, Inc.
Phone: 512-697-8224
cmackie@emergenttechnologies.com